SCHEMBL2897758

SCHEMBL2897758

CCOC(=O)c1c(O)c2c(-c3ccccc3)csc2[nH]c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.47
GSTO1 P78417 1/20 0.47
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 4/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 2/20 0.47
ALOX12 P18054 2/20 0.47
KMT2A Q03164 2/20 0.47
PRKCZ Q05513 1/20 0.46
POLB P06746 3/20 0.46
RAB9A P51151 1/20 0.46
PRKAB2 O43741 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PRKAG3 Q9UGI9 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5919158 0.91 PRKAB2 (0.58) LMNAALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL5919390 0.89 PRKCZ (0.47) ALDH1A1MAPTHTTPRKCZPRKAB2
SCHEMBL2897779 0.89 PRKCZ (0.57) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL4155315 0.82 ALDH1A1 (0.50) LMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL2902729 0.80 MAPT (0.55) LMNAALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL14341981 0.74 CSF1R (0.53) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL1189659 0.74 PRKAB2 (0.52) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL31526164 0.73 LMNA (0.62) LMNAGSTO1ALDH1A1SMN1; SMN2MAPT
SCHEMBL31618843 0.73 LMNA (0.62) LMNAGSTO1ALDH1A1SMN1; SMN2MAPT
SCHEMBL1119013 0.73 PRKAB2 (0.51) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193215-B2 Thieno[2 3-b]pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2012-06-05 US disclosed
EP-1879899-B1 THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-08-04 EP disclosed
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors XENTION LIMITED (GB) 2010-02-18 US disclosed
US-7576212-B2 Thieno[2,3-B] pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2009-08-18 US disclosed
EP-1879899-A1 THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2008-01-23 EP disclosed
US-20060183768-A1 Compounds XENTION DISCOVERY LTD. (GB) 2006-08-17 US disclosed
WO-2006061642-A1 COMPOUNDS XENTION DISCOVERY LIMITED (GB) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors SCN8A, SCN1B, SCN2B LMNA 2770/4885GSTO1 1610/4885ALDH1A1 3155/4885
US-20060183768-A1 Compounds SCN7A, CBR3, SCN8A LMNA 2895/4885GSTO1 1266/4885ALDH1A1 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.